January 15, 2026

Rebuilding the Lacrimal Blueprint

Autophagy: an unexpected gatekeeper of lacrimal gland development

The Ophthalmologist

January 14, 2026

Why I Built a Beauty Brand as an Ophthalmologist

Bridging the divide between eye health and cosmetics represents the natural evolution of compassionate, patient-centered care

The Ophthalmologist

January 14, 2026

Asymptomatic Meibomian Gland Characteristics 

Silent gland failure: what do asymptomatic adults reveal about subclinical MGD?

The Ophthalmologist

December 02, 2025

FDA Approves Amneal’s Cyclosporine Ophthalmic Emulsion 0.05% for Dry Eye

Cyclosporine ophthalmic emulsion 0.05% is the generic equivalent of Restasis, a registered trademark of Allergan, an AbbVie company.

Optometric Management

December 02, 2025

FDA Approves Amneal’s Cyclosporine Ophthalmic Emulsion 0.05% for Dry Eye

Cyclosporine ophthalmic emulsion 0.05% is the generic equivalent of Restasis, a registered trademark of Allergan, an AbbVie company.

Ophthalmology Management

November 01, 2024

Spotlight on Technology & Technique: Double Teaming Dry Eye

In November 2023, Lumenis Vision announced OptiPLUS, a dual-frequency RF device that delivers heat across various tissue layers, increasing blood circulation.

Ophthalmology Management

July 01, 2024

GUEST EDITORIAL: My Corneal Playlist

The process of curating content for this issue of Corneal Physician was the same process I use to select songs. Only instead of asking myself, “what songs should be on this playlist,” (David Guetta’s “Titanium” is a must track for a any club, by the way), I asked myself, “What topics should be in this issue?” What follows is my corneal playlist, each accompanied by fantastic artists.

Corneal Physician

January 01, 2024

CLINICAL: Dry Eye: A welcomed reminder

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Optometric Management

May 21, 2025

Small Drop, Big Impact

Could Miebo represent a genuine innovation for ocular surface disease (OSD) treatment and management?

The Ophthalmologist